The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khovasova N.O.

Pirogov Russian National Research Medical University, Moscow, Russia;
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University, Moscow, Russia

Moroz V.I.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University, Moscow, Russia

Tkacheva O.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russia

The place of chondroitin sulfate and glucosamine sulfate in osteoarthritis pain therapy: a practical view from evidence-based medicine

Authors:

Khovasova N.O., Moroz V.I., Tkacheva O.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9): 112‑117

DOI: 10.17116/jnevro2019119091112

Read: 7980 times

Download PDF (RU)
Contact the author
Table of contents

THE PLACE OF CHONDROITIN SULFATE AND GLUCOSAMINE SULFATE IN OSTEOARTHRITIS PAIN THERAPY: A PRACTICAL VIEW FROM EVIDENCE-BASED MEDICINE
THE PLACE OF CHONDROITIN SULFATE AND GLUCOSAMINE SULFATE IN OSTEOARTHRITIS PAIN THERAPY: A PRACTICAL VIEW FROM EVIDENCE-BASED MEDICINE

To cite this article:

Khovasova NO, Moroz VI, Tkacheva ON. The place of chondroitin sulfate and glucosamine sulfate in osteoarthritis pain therapy: a practical view from evidence-based medicine. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):112‑117. (In Russ.)
https://doi.org/10.17116/jnevro2019119091112

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Painful diabetic poly­neuropathy in patients with cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):64-72
Inflammatory aging. Part 2. Are there diagnostic biomarkers available. Russian Journal of Preventive Medi­cine. 2025;(1):89-95
Aseptic osteitis of the tibia after intraarticular inje­ction of hyaluronic acid in a patient with knee osteoarthritis. Russian Journal of Archive of Pathology. 2025;(2):69-72
Use of a fixed combination of diclofenac and orphenadrine (Neodolpasse) for postoperative analgesia after exte­nded gastrectomy with rese­ction of the lower third of the esophagus. P.A. Herzen Journal of Onco­logy. 2025;(2):52-56
Review and reso­lution of the Council of Expe­rts on the topic «The role of the combination of unde­natured type II collagen UC-II, vita­min C, and trace elements in reco­vering and maintaining the function of the musculoskeletal system, and preservation of health of the joints». Russian Journal of Preventive Medi­cine. 2025;(4):102-110
The fundamental foundations of periodontal aging. Part 1. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2):63-69
Myofascial orofacial pain: clinical and pathogenetic mechanisms, possibilities of botu­linum therapy. Russian Journal of Pain. 2025;(2):12-23
Prevalence of chro­nic pain in adult popu­lation of the Russian Fede­ration: an all-Russian epidemiological study. Russian Journal of Pain. 2025;(2):54-62
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

Osteoarthritis is one of the leading causes of a chronic pain in elderly people. Old and very old age in itself is a risk factor of a comorbidity, which often limits the therapy specified in clinical recommendations. First of all, it concerns NSAID. In such situations, priority is given to chondroitin sulfate (CS) and glucosamine sulfate (GS) having the anti-inflammatory properties comparable with effects of NSAID. CS and GS also promote the delay in progression of degenerative processes and restoration of the structure of cartilaginous tissue. The drugs of CS and GS groups are Chondroguard and Sustaguard Artro having the considerable evidence-based efficacy and safety and also a polymodality of effects in patients with a combination of osteoarthritis and socially important diseases (atherosclerosis, diabetes mellitus type 2, oncological diseases) and also geriatric syndromes (sarcopenia) and aging in general.

Keywords:

osteoarthritis
chronic pain
ageing
geriatric syndrome
socially significant diseases
NSAID
chondroitin sulfate
Chondroguard
glucosamine sulfate
Sustaguard Artro

Authors:

Khovasova N.O.

Pirogov Russian National Research Medical University, Moscow, Russia;
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University, Moscow, Russia

Moroz V.I.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University, Moscow, Russia

Tkacheva O.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russia

Close metadata

References:

  1. Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford). 2002;41(suppl 1):3-6.
  2. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, Bruyère O, Guillemin F, Hochberg MC, Hunter DJ, Kanis JA, Kvien TK, Laslop A, Pelletier JP, Pinto D, Reiter-Niesert S, Rizzoli R, Rovati LC, Severens JL, Silverman S, Tsouderos Y, Tugwell P, Reginster JY. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43(3):303-313.
  3. Teirlinck CH, Dorleijn DMJ, Bos PK, Rijkels-Otters JBM, Bierma-Zeinstra SMA, Luijsterburg PAJ. Prognostic factors for progression of osteoarthritis of the hip: a systematic review. Arthritis Research & Therapyvolume. 2019;21:192.
  4. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019. https://doi.org/10.1016/j.joca.2019.06.011
  5. Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, Luisa Brandi M, Kanis JA, Altman RD, Hochberg MC, Martel-Pelletier J, Reginster JY. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4 suppl):3-11.
  6. Reginster JY, Cooper C, Hochberg M, Pelletier JP, Rizzoli R, Kanis J, Abadie E, Maheu E, Brandi ML, Devogelaer JP, Branco J, Herrero-Beaumont G, D’Hooghe P, Bruyère O. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin. 2015;31(5):1041-1045.
  7. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. International Journal of Rheumatology. 2011;969012. https://doi.org/10.1155/2011/969012
  8. Martel-Pelletier J, Farran A, Montell E, Vergés J, Pelletier JP. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015;20(3):4277-4289.
  9. Honvo G, Bruyere O, Geerinck A, Veronese N, Reginster J-Y. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019;36:1085-1099. https://doi.org/10.1007/s12325-019-00921-w
  10. Bruye`re O, Cooper C, Al-Daghri NM, Dennison EM, Rizzoli R, Reginster JY. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018;30:111-117.
  11. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical- grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76:1537-1543. https://doi.org/10.1136/annrheumdis-2016-210860
  12. Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol. 1997;24(4):779-781.
  13. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009;61:1271-1280.
  14. Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster J-Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, rand- omized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:524-533. https://doi.org/10.1002/art.24255
  15. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-con- trolled trials of 2-year duration. Osteoarthr Cartil. 2010;18:28-31.
  16. Singh JA, Noorbaloochi S, Macdonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews. 2015. https://doi.org/10.1002/14651858.cd005614.pub2
  17. Zegels B, Crozes P, Uebelhart D, Bruyère O, Reginster JY. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteo- arthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21:22-27. https://doi.org/10.1016/j.joca.2012.09.017
  18. Bruyere O. Pharmaceutical-grade chondroitin sulfate in the management of knee osteoarthritis. Expert Opin Pharmacother. 2018;19:409-412. https://doi.org/10.1080/14656566.2018.1442438
  19. Shang Q, Yin Y, Zhu L, Li G, Yu G, Wang X. Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. International Journal of Biological Macromolecules. 2016;86:112-118.
  20. Alekseeva LI, Sharapova EP, Kashevarova NG, Taskina EA, Lila AM, Bogdanov AN, Bozhkova SA, Bagrecova AA, Noskov SM, Grunina EA. Comparative study of the efficacy and safety of Chondroguard during its combined (intra-articular and intramuscular) and intramuscular injection in patients with kneeosteoarthritis. Sovremennaya Revmatologiya. 2018;12(2):44-49. (In Russ.) https://doi.org/10.14412/1996-7012-2018-2-44-49
  21. Vasil’eva LV, Evstratova EF, Nikitin AV, Burdina NS. Study of different pharmaceutical. forms and pathogenic therapy regimen effectiveness for back and joint pain treatment in comorbid patients with osteoarthritis. Consilium Medicum. 2019;21(2):69-73. (In Russ.) https://doi.org/10.26442/20751753.2019.2.190244
  22. Gromova OA, Torshin IYu, Lila AM, Naumov AV, Reier IA, Karateev AE. Differential chemoreactome analysis of glucosamine sulfate and non-steroidal anti-inflammatory drugs: promising synergistic drug combinations. Sovremennaya Revmatologiya. 2018;32:36-43. (In Russ.) https://doi.org/10.14412/1996-7012-2018-2-36-43
  23. Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, de la Torre Hernández J, Montell E, Jiménez W, Edelman E, Balcells M. Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response. Thromb Haemost. 2018;118(7):1329-1339. https://doi.org/10.1055/s-0038-1657753
  24. Gromova OA, Torshin IYu, Lila AM, Naumov AV, Rudakov KV. On the safety of glucosamine sulfate in patients with insulin resistance. Consilium Medicum. 2019;21(4):75-83. (In Russ.) https://doi.org/10.26442/20751753.2019.4.190309
  25. Gromova OA, Torshin IYu, Lila AM, Romanov IS, Nazarenko AG. Systematic study review on antitumor effects of glucosamine and chondroitin sulfate cartilage protectors. RMZh «Medicinskoe Obozrenie». 2019;4(I):4-10. (In Russ.)
  26. Stabler TV, Huang Z, Montell E, Vergés J, Kraus VB. Chondroitin sulphate inhibits NF-κB activity induced by interaction of pathogenic and damage associated molecules. Osteoarthritis and Cartilage. 2017;25:1.
  27. Fioravanti A, Collodel G. In Vitro Effects of Chondroitin Sulfate. Advances in Pharmacology. 2006;53:449-465.
  28. Takeuchi S, Nakano S-I, Nakamura K, Ozoe A, Chien P, Yoshihara H, Hakuno F, Matsuwaki T, Saeki Y, Takahashi S-I, Yamanouchi K, Nishihara M. Roles of chondroitin sulfate proteoglycan 4 in fibrogenic/adipogenic differentiation in skeletal muscle tissues. Experimental Cell Research. 2016;347(2):367-377.
  29. Taşkesen A, Ataoğlu B, Özer M, Demirkale İ, Turanli S. Glucosamine-chondroitin sulphate accelerates tendon-to-bone healing in rabbits. Eklem Hastalik Cerrahisi. 2015;26(2):77-83.
  30. Petersen SG, Beyer N, Hansen M, Holm L, Aagaard P, Mackey AL, Kjaer M. Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients. Arch Phys Med Rehabil. 2011;92(8):1185-1193.
  31. Pocobelli G, Kristal AR, Patterson RE, Potter JD, Lampe JW, Kolar A, Evans I, White E. Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr. 2010;91:1791-1800.
  32. Katoh A, Kai H, Harada H, Niiyama H, Ikeda H. Oral Administration of Glucosamine Improves Vascular Endothelial Function by Modulating Intracellular Redox State. International Heart Journal Association. 2017;58(6):926-932.
  33. Gromova OA, Torshin IYu, Lila AM, Naumov AV, Rudakov KV. Chemoreactome analysis of the antithrombotic effects of glucosamine sulfate and nonsteroidal anti-inflammatory drugs. Sovremennaya Revmatologiya. 2019;13(1):129-134. (In Russ.)
  34. Torshin IYu, Gromova OA, Naumov AV, Lila AM. Chemical transcriptome analysis of glucosamine sulfate molecule in the context of post-genomic pharmacology. RMZh. 2019;1(1):1-8. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.